Send to:

Choose Destination
See comment in PubMed Commons below
Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56.

Trastuzumab (herceptin) for early-stage breast cancer.

Author information

  • 1Medical Oncology Clinic, Jules Bordet Institute, l'Universit√© Libre de Bruxelles, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.


Breast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free and overall survivals. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, has been shown to benefit patients who have HER2-positive metastatic breast cancer, and recently, the results of five adjuvant trials involving more than 13,000 women have been released. Here, the authors summarize the main results and outline the differences among these trials, which have demonstrated an important role of trastuzumab in the treatment of women who have HER2-overexpressing/amplified early breast cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk